Treatment with Ultomiris (ravulizumab) led to rapid blood and kidney recovery in a 12-year-old girl with atypical hemolytic uremic syndrome (aHUS) associated with a rare genetic mutation, according to a case report. The girl developed acute kidney failure, thrombocytopenia (low counts of platelets, small cell fragments that help…
News
Factor XIII (FXIII) activity was lower in samples collected during acute episodes of atypical hemolytic uremic syndrome (aHUS), while levels of one of its subunits, FXIII-B, were higher in samples collected during remission, suggesting FXIII-B may serve as a marker of disease activity. “Free FXIII-B emerges as a promising…
Developing atypical hemolytic uremic syndrome (aHUS) complicated the recovery of a baby boy with typical hemolytic uremic syndrome (HUS) — a related condition caused by an infection — but prompt treatment with the approved infusion med Soliris (eculizumab) led to a complete recovery. That’s according to a case…
The sequential use of immune-modulating medications to treat multiple sclerosis (MS), an inflammatory disease that affects the brain and spinal cord, triggered atypical hemolytic uremic syndrome (aHUS) in a 48-year-old woman, according to a case study. This case highlights “the importance of continuous clinical and laboratory monitoring in…
A woman with atypical hemolytic uremic syndrome (aHUS) developed severe complications affecting the kidneys, brain, and heart, but recovered without lasting neurological damage after prompt treatment that included the complement blocker Soliris (eculizumab), a study showed. The complement cascade is a part of the immune system that is…
Rapid response to treatment was associated with better outcomes among adults with biopsy-confirmed thrombotic microangiopathy (TMA), a group of conditions that includes atypical hemolytic uremic syndrome (aHUS), a small study suggested. “These findings highlight the potential importance of timely recognition and close monitoring of treatment response in patients with…
One year of treatment with Elizaria — a drug similar to the U.S.-approved therapy Soliris (eculizumab) — for atypical hemolytic uremic syndrome (aHUS) was found to be safe and to help stabilize kidney function among people with the genetic disease taking part in a study in Russia. The results…
Treatment with Ultomiris (ravulizumab) successfully prevented disease recurrence in a middle-aged man whose atypical hemolytic uremic syndrome (aHUS) was linked to a novel mutation — one believed to put him at a high risk for relapse — in the CFH gene, a case report from Japan shows. During the…
Ultomiris (ravulizumab) is a safe and effective way to prevent disease recurrence in people with atypical hemolytic uremic syndrome (aHUS) who undergo a kidney transplant, a real-world study in Spain shows. Data from 68 adult patients found that six months of treatment led to significant improvements in blood…
Starting treatment with Ultomiris (ravulizumab) led to rapid clinical improvement — with recovery of kidney function — for a young man with a history of kidney transplant who developed atypical hemolytic uremic syndrome (aHUS) after a severe viral lung infection. According to a report detailing the case, the…
Recent Posts
- No answers about what’s causing severe inflammation and swelling
- Approved treatment helps girl recover from severe aHUS, report shows
- Blood protein may help track disease activity in people with aHUS
- Just along for the ride on the roller coaster of life with chronic illness
- Developing aHUS complicates baby’s HUS recovery, but drug helps
- Sequential MS treatments trigger aHUS in woman: Case study
- Prompt treatment leads to full recovery in severe aHUS case: Report
- My hysterectomy was one of the easiest parts of my medical journey
- Early treatment response tied to better outcomes in adults with TMA
- Drug similar to Soliris safe, shows long-term benefits for treating aHUS